Placental proteins and steroid hormones in the soluble fraction of human syncytiotrophoblast plasma membrane

Placental protein 5 (PP5), pregnancy-specific glycoprotein (SP1), pregnancy-associated alpha 2-glycoprotein (SP3) and chorionic gonadotrophin could not be demonstrated in appreciable molar quantities in the soluble fraction from microvillous plasma membrane preparations isolated from the syncytiotrophoblast of full-term human placentae. However, progesterone, total oestriol and placental lactogen may have some association with this membrane.     

Measurement of integrated sensory-motor function following brain damage by a computerized preview tracking task

A preview tracking task has been developed which has particular application to neurological assessment and rehabilitation. Generated and monitored by a graphic display computer, it permits accurate global quantification of the upper-limb sensory-motor system. The incorporation of 'preview' into the tracking task is considered to significantly increase its effectiveness and relevance in relation to normal daily activities. Applied to three groups of normal subjects, several features of normal psychomotor performance and learning were identified or verified: hand dominance is not significant in overall arm control; learning does not completely plateau; increase in age (15-59 years) results in only a minor overall decrement in performance; an initial wide performance distribution decreases dramatically in subsequent sessions. Applied to brain-damaged patients, particularly head injury or stroke, the preview tracking task allows assessment at regular intervals enabling sensory-motor recovery curves to be generated. The potential of this technique, to help determine the efficacy of therapeutic procedures on the recovery process, is illustrated with the presentation of results from three brain-damaged patients demonstrating zero, significant and disjointed recovery of sensory-motor function. The usefulness of the preview tracking task can be expanded by combination with a less frequently applied but more component specific neurological assessment battery.     

A new case of the unstable haemoglobin Genova (alpha 2 beta 2 28 (beta 10) leu leads to pro) in Canada: as a result of sporadic mutation and causing Heinz body haemolytic anaemia

The first case of the unstable Hb Genova as a result of sporadic mutation is described. It is found in a 3-year-old Canadian boy of East Indian extraction with chronic Heinz body haemolytic anaemia.     

The CTFA Evaluation of Alternatives Program: an evaluation of in vitro alternatives to the Draize primary eye irritation test. (Phase III) surfactant-based formulations

The CTFA Evaluation of Alternatives Program is an evaluation of the relationship between data from the Draize primary eye irritation test and comparable data from a selection of promising in vitro eye irritation tests. In Phase III, data from the Draize test and 41 in vitro endpoints on 25 representative surfactant-based personal care formulations were compared. As in Phase I and Phase II, regression modelling of the relationship between maximum average Draize score (MAS) and in vitro endpoint was the primary approach adopted for evaluating in vitro assay performance. The degree of confidence in prediction of MAS for a given in vitro endpoint is quantified in terms of the relative widths of prediction intervals constructed about the fitted regression curve. Prediction intervals reflect not only the error attributed to the model but also the material-specific components of variation in both the Draize and the in vitro assays. Among the in vitro assays selected for regression modeling in Phase III, the relationship between MAS and in vitro score was relatively well defined. The prediction bounds on MAS were most narrow for materials at the lower or upper end of the effective irritation range (MAS = 0-45), where variability in MAS was smallest. This, the confidence with which the MAS of surfactant-based formulations is predicted is greatest when MAS approaches zero or when MAS approaches 45 (no comment is made on prediction of MAS > 45 since extrapolation beyond the range of observed data is not possible). No single in vitro endpoint was found to exhibit relative superiority with regard to prediction of MAS. Variability associated with Draize test outcome (e.g. in MAS values) must be considered in any future comparisons of in vivo and in vitro test results if the purpose is to predict in vivo response using in vitro data.     

Success of surgery for primary aldosteronism judged by residual autonomous aldosterone production

Since February 1996 we have prospectively assessed residual adrenal autonomy by the fludrocortisone suppression test (FST) in 23 patients 3 months after unilateral adrenalectomy for Conn syndrome and in 45 patients after a longer interval. In regard to blood pressure, 36 (53%) patients were cured of hypertension and the remaining 32 (47%) patients had improved hypertension control at the time of their latest postoperative clinical assessment. In regard to the outcome of surgery, patients who achieved normal suppressibility of aldosterone were regarded as cured, and those who had greater suppressibility after surgery were considered improved. Time since surgery for the whole group averaged 26 months. By these biochemical criteria, 42 patients (62%) were cured by surgery, and the rest improved; 16 (76%) of 21 women were cured, and 26 (55%) of 47 men. The women (mean +/- SD age 47 +/- 11 years) were significantly (p < 0.05) younger than the men (52 +/- 9 years). Preoperative aldosterone levels before and after FST were similar in the cured and improved groups and fell significantly (p < 0.01) in both groups following surgery. After surgical reduction of autonomous aldosterone production, mean plasma renin activity levels increased sixfold in the cured group and threefold in the improved group. Surgical mortality in this group of 68 patients with Conn syndrome was zero.